STINGing Antitumor Immunity into Action.
Efforts to stimulate STING signaling, thereby turning immunologically "cold" tumors "hot" and receptive to immunotherapy, are gaining ground in the industry. To date, directly targeting the STING receptor with synthetic ligands is the main approach to have entered clinical trials, but indirect small-molecule modulators of the pathway are also being pursued.